Lupin Receives USFDA Approval for Generic Hyperkalemia Oral Suspension
Pharmaceutical company Lupin has received approval from the U.S. Food and Drug Administration for its generic version of sodium zirconium cyclosilicate oral suspension in 5 g and 10 g packets. This generic drug is bioequivalent to AstraZeneca's Lokelma and is indicated for treating hyperkalemia in adults. Lokelma had estimated annual U.S. sales of approximately USD 568 million, according to IQVIA data from June 2026.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (55/100). Lens Score 40/100.
Outlets measured: news18, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (52–58/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 10 Aug, 01:38 pm. Other outlets followed.